December 09, 2016 10:00 AM ET

Biotechnology

Company Overview of FORMA Therapeutics, Inc.

Company Overview

FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically-driven diseases. The company’s drug discovery engine deploys screening and structure-based approaches across various families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. It has a strategic partnership with Celgene Corporation. FORMA Therapeutics, Inc. was formerly known as Forma Pharmaceuticals, Inc. and changed its name to FORMA Therapeutics, Inc. in February 2008. The company was incorporated in 2007 and is based in Watertown, Massachusetts. The company has an additional chemistry operation in Branford, Connecticut. FORMA Therapeutics, ...

500 Arsenal Street

Suite 100

Watertown, MA 02472

United States

Founded in 2007

Phone:

617-679-1970

Fax:

617-679-1977

Key Executives for FORMA Therapeutics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Director
Chief Financial Officer
Age: 50
Chief Intellectual Property Counsel and Vice President of Legal
Head of Biomolecular Screening and Executive Director
Compensation as of Fiscal Year 2016.

FORMA Therapeutics, Inc. Key Developments

FORMA Therapeutics, Inc. Appoints Jim Winkler as Vice President, Discovery and Translational Biology

FORMA Therapeutics, Inc. announced the appointment of Jim Winkler, Ph.D., as Vice President, Discovery and Translational Biology. Dr. Winkler joins the FORMA leadership team with over 30 years’ experience in the biotechnology and pharmaceutical industry within oncology and inflammation, and most recently served as Chief Scientific Officer at Arvinas, Inc., in New Haven, Connecticut.

FORMA Therapeutics, Inc. Appoints Karoline Shair as Vice President, Legal and Chief Intellectual Property Counsel

FORMA Therapeutics, Inc. announced the appointment of Karoline Shair, Ph.D., J.D., as Vice President, Legal and Chief Intellectual Property Counsel. Karoline joins the FORMA leadership team with over 20 years’ global experience in the biotechnology and pharmaceutical sector. She most recently served as Vice President and IP Region Head, at Takeda Pharmaceuticals International Co., in Cambridge, Massachusetts.

FORMA Therapeutics Enrolls First Patient in Phase 1 Study of FT-1101 in Advanced Hematological Malignancies

FORMA Therapeutics announced the initiation of a Phase 1 study of FT-1101, with the first dose administration in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. FT-1101 is an oral, structurally distinct and potent pan-inhibitor of the BET (Bromodomain and Extra-Terminal) epigenetic protein family. Small molecule inhibition of BET results in down-regulation of the critical oncogene MYC, a master regulator of diverse cell functions critical for cell growth and survival in many cancers. At tolerated doses in human tumor xenograft mousemodels, FT-1101 has demonstrated significant anti-tumor activity including tumor regressions. FT-1101 is part of FORMA’s second global strategic collaboration with Celgene Corporation announced in April 2014. Celgene has obtained an exclusive EU license for FT-1101 in exchange for an undisclosed payment to FORMA. Under the terms of the collaboration agreement, FORMA will advance the FT-1101 program through Phase 1, and Celgene will be responsible to fund and execute further global clinical development. The Phase 1 multicenter, open-label, dose escalation clinical trial is designed to assess the safety and tolerability of FT-1101 capsules as a single agent. FT-1101 will be administered orally on a once weekly dosing schedule in a 28-day cycle. The study will enroll patients with relapsed refractory AML and high risk myelodysplastic syndrome. Key objectives in the study include determination of a maximum tolerated dose, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of FT-1101.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact FORMA Therapeutics, Inc., please visit www.formatherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.